In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.
Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.
The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.
NEW YORK – Novartis on Thursday announced it has acquired Kate Therapeutics to bolster its capabilities to develop gene therapies for inherited neuromuscular diseases. In the transaction valued at ...